Marc Mejias

mmmm

Contact: mmejias@clinic.cat

Academic Role: Postdoctoral Researcher

Biography: Marc Mejias (Barcelona, 1978) earned his Bachelor’s of Science degree in Biology from the University of Barcelona in 2003 and his Ph.D. degree in Biology from the University of Barcelona in 2010. He was awarded with a Predoctoral Fellowship from the Spanish Ministry of Science. Furthermore, his doctoral thesis entitled “Role of angiogenesis in the pathophysiology of portal hypertension”, directed by Mercedes Fernandez, received the Excellent Cum Laude qualification and was awarded with the University of Barcelona Extraordinary Doctorate Prize for the academic year 2009/2010. He has also earned the professional Certificate in Training on Experimental Animal Use and Design of Research Projects of the University of Barcelona (2003), the Certificate in Introduction to Flow Cytometry from IDIBAPS (2016), and participates in the oficial IDIBAPS Training Programme for Pre and Postdoctoral Researchers (from 2016). He also participated as a Faculty Member in the Basic School of Hepatology of the European Association for the Study of Liver (Barcelona, October 2018). Marc joined the Mercedes Fernandez Lab in June 2003.

Publications

Pericytes in the gut

Ramirez M, Pell N, Mejias M, Fernandez M

Co-first authors: Marta Ramirez and Nuria Pell

Corresponding author: Mercedes Fernandez

Advances in Experimental Medicine and Biology 2019; 1122:73-100, “Pericyte Biology in Different Organs”, Ed. A. Birbrair. Springer Nature, Switzerland AG 

Invited Review

Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension

Gallego J, Garcia-Pras E, Mejias M, Pell N, Schaeper U, Fernandez M

Co-first authors: Javier Gallego and Ester Garcia-Pras

Corresponding author: Mercedes Fernandez

Scientific Reports 20177:14791-14806  PubMed    Springer Nature SharedIt

Gene therapy with endothelial-specific liposomal short interfering siRNA targeting kinase insert domain receptor inhibits portosystemic collateralization in portal hypertension

Gallego J, Garcia-Pras E, Mejias M, Pell N, Schaeper U, Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology 2017; 66:141A

This abstract has been presented in Parallel Session at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) (Washington DC, 2017). The speaker and coauthor, Nuria Pell, has been awarded with the 2017 Basic Science Young Investigator Travel Award from AASLD, which recognizes outstanding young basic science researchers working on liver disease. 

Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension

Garcia-Pras E, Gallego J, Coch L, Mejias M, Fernandez-Miranda G, Pardal R, Bosch J, Mendez R, Fernandez M

Corresponding author: Mercedes Fernandez

Gut 2017; 66:1306-1320 PubMed

Sequential functions of CPEB1 and CPEB4 regulate pathologic expression of VEGF and angiogenesis in chronic liver disease

Calderone V, Gallego J, Fernandez-Miranda G, Garcia-Pras E, Maillo C, Berzigotti A, Mejias M, Bava FA, Angulo-Urarte A, Graupera M, Navarro P, Bosch J, Fernandez M, Mendez R

Co-first authors: Vittorio Calderone and Javier Gallego

Co-corresponding authors: Raul Mendez and Mercedes Fernandez

Gastroenterology 2016;150:982-997  PubMed

Pathogenesis of portal hypertension: Extrahepatic mechanisms

Fernandez M, Mejias M, Garcia-Pras E, Gallego J, Pell N, Ramirez M, Naranjo-Suarez S, Barrachina-Catala A 

Corresponding author: Mercedes Fernandez

Current Hepatology Reports 2016;15:199-207   

Invited Review

Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats

Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Gut 201564:657-666 PubMed

Editorial devoted to this article: Vespasiani-Gentilucci U, Rombouts K. Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension. Gut (2015) 64:523-524 Editorial

Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats

Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Mendez R, Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology 201460:633-647 PubMed

Editorial devoted to this article: Chatterjee S. Reversal of vasohibin-driven negative feedback loop of vascular endothelial growth factor/angiogenesis axis promises a novel antifibrotic therapeutic strategy for liver diseases. Hepatology (2014) 60:458-460 Editorial

Hepatology Highlights devoted to this article: Dufour JF. After vasopressin comes vasohibin. Hepatology (2014) 60:447 Highlights

Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats

D’Amico M, Mejias M, Garcia-Pras E, Abraldes JG, Garcia-Pagan JC, Fernandez M, Bosch J

American Journal of Physiology 2012;302:G1191-G1198 PubMed

Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension

Mejias M, Garcia-Pras E, Gallego J, Mendez R, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Hepatology 201152:529-539 PubMed

Effects of the combined administration of sorafenib plus propranolol on portal hypertension in cirrhotic rats

D’Amico M, Mejias M, Garcia-Pras E, Abraldes J, Garcia-Pagan JC, Fernandez M, Bosch J

Journal of Hepatology 2010; 52:S203

This abstract has been presented at the International Liver Congress of the European Association for the Study of the Liver (EASL) (Vienna, Austria, 2010)

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology 2009;49:1245-1256 PubMed

Editorial devoted to this article: Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? Hepatology (2009) 49:1066-1068 Editorial

Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension

Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Hepatology 200950:296-305 PubMed

Bone morphogenetic proteins (BMP) and BMP signalling are significantly increased in experimental models of cirrhosis and portal hypertension

De Gottardi A, Mejias M, Garcia-Pras E, Rodriguez-Vilarrupla A, Garcia-Pagan JC, Fernandez M, Bosch J

Journal of Hepatology 2009; 50:S17

This abstract has been presented at the International Liver Congress of the European Association for the Study of the Liver (EASL) (Copenhagen, Denmark, 2009)

The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats

Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Cellular and Molecular Medicine 2008;12: 1690-1699 PubMed

Role of angiogenesis in portal hypertension

Fernandez M, Mejias M, Garcia-Pras E, Bosch J

Corresponding author: Mercedes Fernandez

In: Liver Cirrhosis: From Pathophysiology to Disease Management 2008Edited by: Bosch J, Burroughs AK, Lammert F, Sauerbruch T, Lebrec D. Springuer, Dordrecht, The Netherlands. Volume 162, pages 112-129

Invited Review

Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension

Coll M, Genesca J, Raurell I, Rodriguez-Vilarrupla A, Mejias M, Otero T, Oria M, Esteban R, Guardia J, Bosch J, Martell M.

Journal of Hepatology 2008; 49:43-51

Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats

Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J

Corresponding author: Mercedes Fernandez

Hepatology 2007;46:1208-1217 PubMed

This paper received the Award to the Best Publication in Hepatology Research (Year 2007), from the Spanish Association for the Study of the Liver

NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats

Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J

Corresponding author: Mercedes Fernandez

Gut 2007;56:560-564 PubMed

The somatostatin analogue octreotide inhibits angiogenesis and VEGF expression in early, but not late, stages of portal hypertension in rats. Role of somatostatin receptor subtype 2 downregulation during the evolution of the portal hypertensive syndrome

Mejias M, Garcia-Pras E, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology 2007; 46:607A

This abstract has been presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (Boston, MA, US, 2007)

Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats

Angermayr B, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J, Fernandez M 

Corresponding author: Mercedes Fernandez

Journal of Hepatology 2006; 44:1033-1039 PubMed

NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperemia in portal hypertensive rats

Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J

Corresponding author: Mercedes Fernandez

Hepatology 2006; 44:358A

This abstract has been presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (Boston, MA, US, 2006)

Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats

Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J 

Corresponding author: Mercedes Fernandez

Journal of Hepatology 2005; 43:98-103 PubMed

Editorial devoted to this article: Moreau R. “VEGF-induced angiogenesis drives collateral circulation in portal hypertension”. J Hepatol 2005;43:6-8 Editorial

Oxidative stress contributes to the hyperdynamic circulation in portal hypertensive rats

Angermayr B, Mejias M, Garcia-Pagan JC, Rodes J, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Hepatology 2005; 42:63

This abstract has been presented at the International Liver Congress of the European Association for the Study of the Liver (EASL) (Paris, France, 2005)

Contribution of heme oxygenase to the splanchnic hyperdynamic circulation in portal hypertensive rats: Interaction with nitric oxide synthase

Angermayr B, Fernandez M, Mejias M, Garcia-Pagan JC, Rodes J, Bosch J

Corresponding author: Mercedes Fernandez

Hepatology 2004; 40:484A

This abstract has been presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (Boston, MA, US, 2004)

Inhibition of VEGF receptor-2 (VEGFR-2) signaling prevents portal-systemic collateral (PSC) vessel formation in rats with portal hypertension

Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J

Corresponding author: Mercedes Fernandez

Journal of Hepatology 2004; 40:4

This abstract has been presented at the International Liver Congress of the European Association for the Study of the Liver (EASL) (Berlin, Germany, 2004)

Heme oxygenase protects against oxidative stress, inflammation, and inflammatory angiogenesis in portal hypertension

Angermayr B, Fernandez M, Mejias M, March S, Gracia-Sancho J, Garcia-Pagan JC, Rodes J, Bosch J

Corresponding author: Mercedes Fernandez

Hepatology 2004; 40:480A

This abstract has been presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (Boston, MA, US, 2004)

 

 

 

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies